Skip to main content
Gencurix Inc. logo

Gencurix Inc. — Investor Relations & Filings

Ticker · 229000 ISIN · KR7229000005 KO Manufacturing
Filings indexed 405 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country KR South Korea
Listing KO 229000

About Gencurix Inc.

https://www.gencurix.com/eng/

Gencurix Inc. is a molecular diagnostics company that develops and commercializes diagnostic solutions for precision medicine. The company's portfolio focuses primarily on oncology, offering prognostic, companion, and early detection tests. Key products include GenesWell BCT, a multigene prognostic test for early-stage breast cancer, and the GenesWell ddEGFR Mutation Test, a ddPCR-based companion diagnostic. Gencurix also utilizes its Droplex liquid biopsy platform for early cancer detection and develops diagnostic tests for infectious diseases. The company's core technologies include digital droplet PCR (ddPCR), real-time PCR, and liquid biopsy for analyzing circulating tumor cells (CTCs) and cell-free DNA (cfDNA).

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Regulatory Filings
2026-05-08 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 91% confidence The document is a Korean “주식등의 대량보유상황보고서(일반)” under the Capital Markets Act – a detailed notification of large shareholdings by a major shareholder and related parties, including share counts, ratios, changes, and underlying contracts. This matches our category for Major Shareholding Notifications (Code: MRQ).
2026-04-09 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document is titled “정기주주총회결과” (“Regular General Meeting of Shareholders Results”) and provides detailed voting outcomes (approval/rejection percentages) for each agenda item at the AGM, including resolutions on financial statements, director and auditor appointments, and amendments. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (Code: DVA).
2026-03-24 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Gencurix' (주식회사 젠큐릭스) for the fiscal year ending December 31, 2025. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. This is a comprehensive financial document, not an announcement or a summary, and fits the definition of an Audit Report/Information (AR). FY 2025
2026-03-16 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides the audit opinion, key financial data, and auditor information for the fiscal year ending 2025-12-31. While it contains financial data, it is a specific regulatory disclosure of the audit report's submission rather than the full annual report (10-K) or a simple announcement of publication (RPA). Given the specific nature of audit report filings in the Korean market, 'AR' (Audit Report / Information) is the most accurate classification. FY 2025
2026-03-11 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company Gencurix. It outlines the date, location, agenda items (such as financial statement approval, director/auditor appointments, and remuneration limits), and details regarding the board's resolution. This document serves as the official notification and proxy-related information for an upcoming Annual General Meeting, which falls under the Proxy Solicitation & Information Statement category.
2026-03-09 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.